Drug Trial Radar · NCT06351527
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
Last checked: Nov 19, 2026Latest source record: Jun 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Apr 23, 2024
Primary completion
Jun 25, 2027
Study completion Oct 25, 2027
Sponsor
- Lead sponsor
- InnoCare Pharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ICP-248 as monotherapy or in combination with anti-CD20 monoclonal antibody in Mature B-cell Malignancies
Conditions
- Mature B-cell Malignancies
Interventions
ICP-248Drug
ICP-248 will be administered orally once daily at escalated doses (starting dose 5/10 mg, maximum 150 mg).
Obinutuzumab (G)Drug
Obinutuzumab will be administered by IV infusion at a dose of 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6.
Rituximab (R)Drug
Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m\^2) at Day 1 per week for 4 weeks during cycle 1, then on day 1 of cycles 3-8, and thereafter once every other cycle up to 2 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: 49 days
- Safety and tolerability of ICP-248 at different doses in B-cell malignanciesTime frame: 5 years
Locations
8 sites in 3 countries. Site status is shown where the registry gives one.
BRCR Medical Center
Plantation, Florida · Recruiting
Clinical Research Alliance
Westbury, New York · Recruiting
Pan American Center for Oncology Trials
San Juan, Puerto Rico · Recruiting
CNE CCOHTPC of Cherkasy Regional Council
Cherkasy, Ukraine · Recruiting
CNE"City Clin Hosp#4"of Dnipro City Council
Dnipro, Ukraine · Recruiting
Medical Center of Limited Liability Company Arensia Exploratory Medicine
Kyiv, Ukraine · Recruiting
Med Center 'Ok!Clinic+' of International Institute of Clinical Trials LLC
Kyiv, Ukraine · Recruiting
SI Institute of Blood Pathology and Transfusion Medicine of AMSU
Lviv, Ukraine · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.